IQVIA

Partner Content

Partner Content

When science and biology combine – the outlook for ADCs in c...

Antibody Drug Conjugates (ADCs) are treatments formed by the conjugation of monoclonal antibodies and cytotoxic agents.

Partner Content

Partner Content

Top 5 challenges of immuno-oncology clinical trials

Learn innovative solutions to address these challenges

Partner Content

IQVIA_infographic_section_NEW_18_11_2017 1

Partner Content

What oncologists need from you when launching a new therapy

At the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is no surprise that two-years on, the number of therapeutic options in cancer care is growin

Partner Content

Partner Content

Oncology – the current landscape and what it means for the f...

The WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for 8.8 million fatalities, yet we are at a point in time where the speed of advancement in underst

Partner Content

Partner Content

How RACE legislation is changing the face of pediatric oncol...

On August 12 of this year the US senate unanimously passed the Race to Accelerate Cures and Equity for Children Act (RACE) expanding on the already enacted Pediatric Research Equity Act (P